Keros Therapeutics Inc. Insider Trading

KROS

Last 12 months

Insiders bought 76K and sold 523K on the open market.

18% of the selling was scheduled in advance under 10b5-1 plans. SVP, General Counsel Esther Cho sold 78K on Feb 18, 11% of their stake, outside a plan.

Net open-market

−447K

6 buys · 12 sales

Under a 10b5-1 plan

18%

of the value sold

Insiders who bought / sold

1 / 9

executives and directors

Last open-market buy

Aug 2026

Aug 17, 2026

Get an email when KROS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 18	Annita Tanini Corp. Controller & VP, Finance	SoldNo plan	1,224	$10.29	13K	2.6%	Form 4
Aug 18	Esther Cho Chief Legal Officer	SoldNo plan	4,485	$10.29	46K	11%	Form 4
Aug 18	Lorena Raquel Lerner Chief Scientific Officer	SoldNo plan	3,568	$10.29	37K	11%	Form 4
Aug 18	Charles W. Newton Director	Sold10b5-1 plan	551	$10.30	6K	4.4%	Form 4
Aug 17	Jean Jacques Bienaime Director	Bought	1,000	$10.27	10K	5.4%	Form 4
Jul 15	Jean Jacques Bienaime Director	Bought	1,000	$10.61	11K	5.7%	Form 4
Jun 15	Jean Jacques Bienaime Director	Bought	1,000	$10.19	10K	6.0%	Form 4
Jun 11	Charles W. Newton Director	Sold10b5-1 plan	550	$10.04	6K	4.2%	Form 4
Jun 4	Julius Knowles Director	Sold10b5-1 plan	2,625	$10.73	28K	2.3%	Form 4
Jun 4	Nima Farzan Director	Sold10b5-1 plan	2,625	$10.73	28K	21%	Form 4
Jun 4	Alpna Seth Director	Sold10b5-1 plan	2,625	$10.72	28K	21%	Form 4
May 15	Jean Jacques Bienaime Director	Bought	1,000	$10.58	11K	12%	Form 4
Apr 15	Jean Jacques Bienaime Director	Bought	1,000	$11.70	12K	13%	Form 4
Mar 9	Jean Jacques Bienaime Director	Bought	2,000	$11.21	22K	37%	Form 4
Feb 19	Jasbir Seehra Chief Executive Officer	SoldNo plan	7,015	$16.17	113K	1.8%	Form 4
Feb 18	Esther Cho SVP, General Counsel	SoldNo plan	4,745	$16.35	78K	11%	Form 4
Feb 18	Lorena Raquel Lerner Chief Science Officer	SoldNo plan	3,873	$16.35	63K	11%	Form 4
Feb 18	Keith Regnante Chief Financial Officer	SoldNo plan	4,739	$16.35	77K	11%	Form 4
Oct 15, 2025	Pontifax (china) IV L.p. Large holder	SoldNo plan 4 parts	4,787,331	$17.75 average	$85M	100%	Form 4
Oct 15, 2025	Daniel Schneeberger Large holder	SoldNo plan 3 parts	5,389,264	$17.75 average	$95.7M	100%	Form 4
Apr 9, 2025	Adar1 Partners, LP Large holder	Bought 5 parts	934,258	$10.13 average	$9.47M	21%	Form 4

Aug 18No plan
Annita Tanini
Corp. Controller & VP, Finance · sold 1,224 at $10.29
13K
2.6% of stake
Aug 18No plan
Esther Cho
Chief Legal Officer · sold 4,485 at $10.29
46K
11% of stake
Aug 18No plan
Lorena Raquel Lerner
Chief Scientific Officer · sold 3,568 at $10.29
37K
11% of stake
Aug 1810b5-1 plan
Charles W. Newton
Director · sold 551 at $10.30
6K
4.4% of stake
Aug 17
Jean Jacques Bienaime
Director · bought 1,000 at $10.27
10K
5.4% of stake
Jul 15
Jean Jacques Bienaime
Director · bought 1,000 at $10.61
11K
5.7% of stake
Jun 15
Jean Jacques Bienaime
Director · bought 1,000 at $10.19
10K
6.0% of stake
Jun 1110b5-1 plan
Charles W. Newton
Director · sold 550 at $10.04
6K
4.2% of stake
Jun 410b5-1 plan
Julius Knowles
Director · sold 2,625 at $10.73
28K
2.3% of stake
Jun 410b5-1 plan
Nima Farzan
Director · sold 2,625 at $10.73
28K
21% of stake
Jun 410b5-1 plan
Alpna Seth
Director · sold 2,625 at $10.72
28K
21% of stake
May 15
Jean Jacques Bienaime
Director · bought 1,000 at $10.58
11K
12% of stake
Apr 15
Jean Jacques Bienaime
Director · bought 1,000 at $11.70
12K
13% of stake
Mar 9
Jean Jacques Bienaime
Director · bought 2,000 at $11.21
22K
37% of stake
Feb 19No plan
Jasbir Seehra
Chief Executive Officer · sold 7,015 at $16.17
113K
1.8% of stake
Feb 18No plan
Esther Cho
SVP, General Counsel · sold 4,745 at $16.35
78K
11% of stake
Feb 18No plan
Lorena Raquel Lerner
Chief Science Officer · sold 3,873 at $16.35
63K
11% of stake
Feb 18No plan
Keith Regnante
Chief Financial Officer · sold 4,739 at $16.35
77K
11% of stake
Oct 15, 2025No plan
Pontifax (china) IV L.p.
Large holder · sold 4,787,331 at avg $17.75
$85M
100% of stake
Oct 15, 2025No plan
Daniel Schneeberger
Large holder · sold 5,389,264 at avg $17.75
$95.7M
100% of stake
Apr 9, 2025
Adar1 Partners, LP
Large holder · bought 934,258 at avg $10.13
$9.47M
21% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch KROS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with KROS

CompareIntrinsic value

PYXSPyxis Oncology, Inc.

$1.66+1.22%10

JANXJanux Therapeutics Inc.

$18.18+2.02%40

NEUPNeuphoria Therapeutics Inc.

$2.98-0.33%10

CVSICV Sciences, Inc.

$0.01-1.00%25

EVMNEvommune, Inc.

$6.04+1.68%35

PRLDPrelude Therapeutics Incorporated

$4.08+7.94%40

EMMAEmmaus Life Sciences, Inc.

$0.03-17.50%21

IRDOpus Genetics Inc.

$4.27+8.65%10

Held by ETFs

KROS is in 14 US ETFs. The largest of them, with KROS's weight in each:

Spot a number that looks wrong? Check it in KROS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing KROS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.